IL308771A - Methods of inhibiting RAS - Google Patents

Methods of inhibiting RAS

Info

Publication number
IL308771A
IL308771A IL308771A IL30877123A IL308771A IL 308771 A IL308771 A IL 308771A IL 308771 A IL308771 A IL 308771A IL 30877123 A IL30877123 A IL 30877123A IL 308771 A IL308771 A IL 308771A
Authority
IL
Israel
Prior art keywords
methods
inhibiting ras
ras
inhibiting
Prior art date
Application number
IL308771A
Other languages
English (en)
Hebrew (he)
Inventor
Kyle Seamon
Original Assignee
Revolution Medicines Inc
Kyle Seamon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc, Kyle Seamon filed Critical Revolution Medicines Inc
Publication of IL308771A publication Critical patent/IL308771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL308771A 2021-05-25 2022-05-25 Methods of inhibiting RAS IL308771A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192837P 2021-05-25 2021-05-25
PCT/US2022/030823 WO2022251292A1 (en) 2021-05-25 2022-05-25 Methods for inhibiting ras

Publications (1)

Publication Number Publication Date
IL308771A true IL308771A (en) 2024-01-01

Family

ID=82115695

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308771A IL308771A (en) 2021-05-25 2022-05-25 Methods of inhibiting RAS

Country Status (11)

Country Link
US (1) US20240277796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346898A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521774A (cg-RX-API-DMAC7.html)
KR (1) KR20240026526A (cg-RX-API-DMAC7.html)
CN (2) CN117715658A (cg-RX-API-DMAC7.html)
AU (1) AU2022281343A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219533A1 (cg-RX-API-DMAC7.html)
IL (1) IL308771A (cg-RX-API-DMAC7.html)
MX (1) MX2023013912A (cg-RX-API-DMAC7.html)
TW (1) TW202313631A (cg-RX-API-DMAC7.html)
WO (1) WO2022251292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4463231A1 (en) * 2022-01-10 2024-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2023232776A1 (en) * 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
PE20252395A1 (es) 2023-02-14 2025-10-10 Hoffmann La Roche Compuestos triciclicos para el tratamiento de cancer
CN121487738A (zh) * 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
TW202446387A (zh) * 2023-04-06 2024-12-01 瑞士商赫孚孟拉羅股份公司 用於治療癌症之三環化合物
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121693329A (zh) * 2023-07-14 2026-03-17 锐新医药公司 治疗ras相关疾病或病症的方法
WO2025162395A1 (zh) * 2024-02-01 2025-08-07 山东先声生物制药有限公司 吲哚衍生物作为ras抑制剂及其应用
CN119431325A (zh) * 2024-10-31 2025-02-14 诚达药业股份有限公司 一种3-(1h-吡唑-1-基)氮杂环丁烷类化合物及其合成方法
WO2026124659A1 (zh) * 2024-12-13 2026-06-18 苏州泽璟生物制药股份有限公司 二羰基类抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317393A (en) 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses
DE102019122206B4 (de) 2019-08-19 2021-07-08 Webasto SE Dachmodul zur Bildung eines Fahrzeugdachs mit Umfeldsensor
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy

Also Published As

Publication number Publication date
TW202313631A (zh) 2023-04-01
US20240277796A1 (en) 2024-08-22
CN117715658A (zh) 2024-03-15
CN118557730A (zh) 2024-08-30
AU2022281343A1 (en) 2023-11-30
MX2023013912A (es) 2024-02-12
JP2024521774A (ja) 2024-06-04
WO2022251292A1 (en) 2022-12-01
CA3219533A1 (en) 2022-12-01
EP4346898A1 (en) 2024-04-10
KR20240026526A (ko) 2024-02-28

Similar Documents

Publication Publication Date Title
IL307396A (en) Methods for inhibiting RAS
IL308193A (en) RAS inhibitors
TWI925825B (zh) Ras抑制劑
IL292643B1 (en) ras inhibitors
GB202001344D0 (en) Ras Inhibitors
IL292642B1 (en) RAS inhibitors
IL274540B (en) Compounds useful for cdk7 inhibition
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
IL281634A (en) Diacosocyclobutanylamino-3-hydroxy-picoline modified amide and its use as a CCR6 inhibitor
EP3636262A4 (en) AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
IL256537A (en) Inhibitors for treating uveal melanoma
GB201807845D0 (en) Kinase Inhibitors
IL271967A (en) Methods for treating congenital hypersecretion of insulin
PT3589637T (pt) Compostos úteis para inibir ror-gamma-t
EP4263533C0 (en) Erap inhibitors
HK40109955A (en) Methods for inhibiting ras
HK40107246A (zh) 抑制ras的方法
SI3589638T1 (sl) Spojine uporabne pri inhibiciji ROR-GAMMA-T
IL313756A (en) Inhibitors of the sestrin-MAPK complex
HK40113167A (en) Ras inhibitors
HK40109254A (zh) Ras抑制剂
GB201914388D0 (en) Kinase inhibitors